Skip to main content

Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.

Conferences
Jiang, S; Terasawa, E; Horton, VG; Ayyagari, R; Waldeck, AR; Halabi, S; Shore, ND
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2020

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2020

Volume

38

Issue

15

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jiang, S., Terasawa, E., Horton, V. G., Ayyagari, R., Waldeck, A. R., Halabi, S., & Shore, N. D. (2020). Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Jiang, Shan, Emi Terasawa, Viviana Garcia Horton, Rajeev Ayyagari, A Reginald Waldeck, Susan Halabi, and Neal D. Shore. “Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2020

Volume

38

Issue

15

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis